RAYMOND MOLDEN: Open Payments
NPI 1477585982 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$592 in 35 payments from 10 companies in 2025. Trend: 2023 $537 · 2024 $464 · 2025 $592
Food & beverage: $592
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $201 |
| Janssen Pharmaceuticals, Inc | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Corium, LLC | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
Products named: VRAYLAR, INVEGA SUSTENNA, TRINTELLIX, INGREZZA, REXULTI, Azstarys, Jornay PM, Auvelity.
Industry payments across AR — which companies pay providers there.
